-+ 0.00%
-+ 0.00%
-+ 0.00%

Chosa Oncology Hosts ESMO Expert Meeting on Personalized Platinum Therapy in Lung Cancer

PUBT·11/09/2026 12:01:01
Listen to the news
Chosa Oncology Hosts ESMO Expert Meeting on Personalized Platinum Therapy in Lung Cancer
  • Chosa Oncology hosted lung cancer experts at ESMO 2026 to discuss personalized platinum therapy using Platin-DRP.
  • Discussions highlighted unmet demand for predicting platinum efficacy; several participants expressed interest in potential collaboration.
  • A November 4, 2026, agreement with a CLIA-certified laboratory partner covers developing and validating Platin-DRP for the US market.
  • First commercial revenue is expected in summer 2027, subject to successful analytical validation.
  • Initial commercial-year sales are forecast at 300-500 tests; estimated US market potential exceeds 250,000 tests annually.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chosa Oncology AB published the original content used to generate this news brief via Cision (Ref. ID: 202611090700BITN____UKPR__EN_20261109-BIT-6691-0) on November 09, 2026, and is solely responsible for the information contained therein.